Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.34
-0.0400-0.43%
Post-market: 9.32-0.0200-0.21%19:34 EDT
Volume:1.85M
Turnover:17.35M
Market Cap:2.37B
PE:-5.27
High:9.49
Open:9.41
Low:9.30
Close:9.38
52wk High:11.22
52wk Low:6.00
Shares:254.11M
Float Shares:221.00M
Volume Ratio:0.76
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7710
EPS(LYR):1.21
ROE:587.33%
ROA:42.62%
PB:-4.29
PE(LYR):7.72

Loading ...

Biocryst to Report Q2 2026 Results, Host Conference Call and Webcast

Reuters
·
Jul 22

Biocryst Names David Jenkins Chief Scientific Officer

Reuters
·
Jul 15

Biocryst Appoints David W. Jenkins as Chief Scientific Officer

THOMSON REUTERS
·
Jul 15

BioCryst (BCRX) Receives a Buy from Wedbush

TIPRANKS
·
Jul 13

Biocryst Pharmaceuticals Price Target Announced at $12.00/share by JP Morgan

Dow Jones
·
Jul 13

J.P. Morgan Initiates a Hold Rating on BioCryst (BCRX)

TIPRANKS
·
Jul 13

Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?

Simply Wall St.
·
Jul 09

Biocryst Pharmaceuticals is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 07

Eupraxia Pharma Adds Robert Bazemore, Amy Pott, Helen Thackray to Board

Reuters
·
Jul 07

Kioxia Ships Next-gen Memory Samples as AI Boom Fuels Dramatic Comeback

Reuters
·
Jul 03

Biocryst Grants New Hires Stock Options for 33,950 Shares at $9.65 Each

Reuters
·
Jul 02

Biocryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 02

Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)

TIPRANKS
·
Jun 30

Biocryst Pharmaceuticals is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jun 30

Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)

TIPRANKS
·
Jun 30

BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End

MT Newswires Live
·
Jun 29

Biocryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Reaffirms Full Year 2026 Orladeyo and Total Company Revenue Guidance

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Shifts Strategic Focus to External Innovation for Rare Disease Pipeline

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - to Make Orladeyo Oral Pellets Available in Early August 2026

THOMSON REUTERS
·
Jun 29